Literature DB >> 17466051

Correlation between patient weight and defects in DNA mismatch repair: is this the link between an increased risk of previous cancer in thinner women with endometrial cancer?

D E Cohn1, J C Pavelka, W L Frankel, C D Morrison, H Hampel, L J Copeland, J M Fowler.   

Abstract

The objective is to determine the relationship between obesity and defects in DNA mismatch repair (MMR) in women with endometrial cancer and to establish whether our previous finding of a higher rate of previous malignancy in thinner women with endometrial cancer is related to these factors. Specimens from 109 patients with primary uterine cancer were used to create a tissue microarray, which was stained with antibodies against MMR genes MLH1, MSH2, MSH6, and PMS2. Genotyping of normal and tumor tissues for microsatellite instability (MSI) was performed. Patients were stratified by body mass index (BMI) and correlated with a history of previous malignancy and defects in MMR. The average BMI of the overall population was 33 kg/m(2). Defective MMR was seen in 22% of tumors. The mean BMI in patients with tumors with MSI was 30.5, compared with 33.8 in microsatellite stable (MSS) tumors (P= 0.06); MSS tumors were more commonly seen in patients with a BMI more than 40 (25% vs 5% in patients with tumors with MSI, P= 0.07). Prior to their diagnosis of endometrial cancer, 16/109 (15%) patients reported having a prior malignancy, 11 (69%) had breast cancer, and 1 had colorectal cancer. Patients with tumors with MSI had previous cancer in 17% of cases, compared with 14% of patients with MSS tumors (P= 0.75). Our previous finding of an increased rate of prior malignancy in thinner patients with endometrial cancer does not appear to be due to alterations in MMR, and hereditary nonpolyposis colorectal cancer-associated cancers are rarely the prior malignancy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17466051     DOI: 10.1111/j.1525-1438.2007.00964.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  13 in total

1.  Body mass index in early adulthood and endometrial cancer risk for mismatch repair gene mutation carriers.

Authors:  Aung Ko Win; James G Dowty; Yoland C Antill; Dallas R English; John A Baron; Joanne P Young; Graham G Giles; Melissa C Southey; Ingrid Winship; Lara Lipton; Susan Parry; Stephen N Thibodeau; Robert W Haile; Steven Gallinger; Loïc Le Marchand; Noralane M Lindor; Polly A Newcomb; John L Hopper; Mark A Jenkins
Journal:  Obstet Gynecol       Date:  2011-04       Impact factor: 7.661

2.  Mismatch repair protein expression in 1049 endometrial carcinomas, associations with body mass index, and other clinicopathologic variables.

Authors:  Amy S Joehlin-Price; Carmen M Perrino; Julie Stephens; Floor J Backes; Paul J Goodfellow; David E Cohn; Adrian A Suarez
Journal:  Gynecol Oncol       Date:  2014-01-17       Impact factor: 5.482

3.  Comparison of lifestyle, hormonal and medical factors in women with sporadic and Lynch syndrome-associated endometrial cancer: A retrospective case-case study.

Authors:  Mari H Aaltonen; Synnöve Staff; Jukka-Pekka Mecklin; Kirsi Pylvänäinen; Johanna U Mäenpää
Journal:  Mol Clin Oncol       Date:  2017-04-06

4.  Case-case study of factors associated to hMLH1, hMSH2, and hMSH6 protein expression among endometrial cancer patients of the University District Hospital of San Juan, Puerto Rico.

Authors:  Lorena González; Ana P Ortiz; Erick L Suárez; Sharee Umpierre; Jorge Billoch; Maria J Marcos; Leilani Joy; Eileen Charneco; Mercedes Y Lacourt; Raúl D Bernabe-Dones; Marcia R Cruz-Correa
Journal:  Int J Gynecol Cancer       Date:  2012-06       Impact factor: 3.437

5.  Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.

Authors:  Daniel D Buchanan; Yen Y Tan; Michael D Walsh; Mark Clendenning; Alexander M Metcalf; Kaltin Ferguson; Sven T Arnold; Bryony A Thompson; Felicity A Lose; Michael T Parsons; Rhiannon J Walters; Sally-Ann Pearson; Margaret Cummings; Martin K Oehler; Penelope B Blomfield; Michael A Quinn; Judy A Kirk; Colin J Stewart; Andreas Obermair; Joanne P Young; Penelope M Webb; Amanda B Spurdle
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

6.  Anthropometric measures and the risk of endometrial cancer, overall and by tumor microsatellite status and histological subtype.

Authors:  Ernest K Amankwah; Christine M Friedenreich; Anthony M Magliocco; Rollin Brant; Kerry S Courneya; Thomas Speidel; Wahida Rahman; Annie R Langley; Linda S Cook
Journal:  Am J Epidemiol       Date:  2013-05-14       Impact factor: 4.897

Review 7.  Current and emerging trends in Lynch syndrome identification in women with endometrial cancer.

Authors:  Kimberly E Resnick; Heather Hampel; Richard Fishel; David E Cohn
Journal:  Gynecol Oncol       Date:  2009-04-17       Impact factor: 5.482

8.  Occult transitional cell carcinoma and Lynch syndrome incidentally revealed after laparoscopic hysterectomy and cystoscopy during staging for endometrial cancer.

Authors:  Vivek Verma; Kalyani Patel; Irene Peregrin; Steven Brandes; Israel Zighelboim
Journal:  Gynecol Oncol Case Rep       Date:  2012-12-14

9.  Endometrial cancer risk and survival by tumor MMR status.

Authors:  Penelope M Webb; Amanda B Spurdle; Christina M Nagle; Tracy A O'Mara; Yen Tan; Daniel D Buchanan; Andreas Obermair; Penny Blomfield; Michael A Quinn
Journal:  J Gynecol Oncol       Date:  2018-02-23       Impact factor: 4.401

10.  Endometrial cancer risk factors among Lynch syndrome women: a retrospective cohort study.

Authors:  Synnöve Staff; Mari Aaltonen; Heini Huhtala; Kirsi Pylvänäinen; Jukka-Pekka Mecklin; Johanna Mäenpää
Journal:  Br J Cancer       Date:  2016-06-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.